Abstract: A method of targeting a pharmaceutical agent to a senescent cell is disclosed. The method comprises administering the pharmaceutical agent to the subject, wherein said pharmaceutical agent is attached to an affinity moiety, said affinity moiety being capable of binding specifically to a polypeptide selected from the group consisting of HSP90B1, DNAJB4, PI4K2A, DBN1, PRKCSH, SPTBN1, NPM1, ITGA3 and a polypeptide set forth in Table 1. The targeting may be for therapeutics or diagnostics.

Abstract: Described herein are anti-human Grp94 antibodies. The antibodies may be used to target senescent cells. Thus, the anti-Grp94 antibodies would be useful in treating diseases and conditions associated with cellular senescence. The anti-Grp94 antibodies could target senescent cells in vivo. Therefore, the anti-Grp94 antibodies could be used to target senescent cells associated with age-related diseases in vivo.

Abstract: A method of targeting a pharmaceutical agent to a senescent cell is disclosed. The method comprises administering the pharmaceutical agent to the subject, wherein said pharmaceutical agent is attached to an affinity moiety, said affinity moiety being capable of binding specifically to a polypeptide selected from the group consisting of HSP90B1, DNAJB4, PI4K2A, DBN1, PRKCSH, SPTBN1, NPM1, ITGA3 and a polypeptide set forth in Table 1. The targeting may be for therapeutics or diagnostics.

Abstract: A method of targeting a pharmaceutical agent to a senescent cell is disclosed. The method comprises administering the pharmaceutical agent to the subject, wherein said pharmaceutical agent is attached to an affinity moiety, said affinity moiety being capable of binding specifically to a polypeptide selected from the group consisting of HSP90B1, DNAJB4, PI4K2A, DBN1, PRKCSH, SPTBN1, NPM1, ITGA3 and a polypeptide set forth in Table 1. The targeting may be for therapeutics or diagnostics.

Abstract: A method of promoting hair growth or reducing hair loss in a subject is disclosed. The method comprises contacting the scalp and skin region in which there is desire for hair growth of the subject with an effective amount of at least one agent which down-regulates an activity and/or an amount of a protein selected from the group consisting of p21, Bcl-xL and Bcl-w. Compositions capable of same are also disclosed.

Abstract: A method of targeting a pharmaceutical agent to a senescent cell is disclosed. The method comprises administering the pharmaceutical agent to the subject, wherein said pharmaceutical agent is attached to an affinity moiety, said affinity moiety being capable of binding specifically to a polypeptide selected from the group consisting of HSP90B1, DNAJB4, PI4K2A, DBN1, PRKCSH, SPTBN1, NPM1, ITGA3 and a polypeptide set forth in Table 1. The targeting may be for therapeutics or diagnostics.

Abstract: A method of treating an inflammatory or fibrotic disease in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent which down-regulates an activity and/or an amount of Bcl-xL and/or Bcl-w and/or p21, with the proviso that the inflammatory disease is not cancer.

Abstract: Fibrosis arises as part of a wound healing response that maintains organ integrity following catastrophic tissue damage, but can also contribute to a variety of human pathologies, including liver cirrhosis. The invention demonstrates that cellular senescence acts to limit the fibrogenic response to tissue damage, thereby establishing a role for the senescence program in pathophysiological settings beyond cancer. Accordingly, the methods of the invention relate to modulating cellular senescence in disease tissue that have elevated numbers of senescent cells, such as in fibrotic tissues.